** Shares of Gyre Therapeutics GYRE.O down 15.3% before the bell to $9.50 after follow-on priced
** San Diego-based biotech late Thurs announced ~2.2 mln shares at $9 for $20 mln gross proceeds
** Offering price represents 19.7% discount to stock's last sale
** Co intends to use net proceeds to fund advancement of its Phase II trial of F351 in metabolic dysfunction-associated steatohepatitis ("MASH”)-associated liver fibrosis in the U.S., for R&D, and manufacturing among other purposes
** Jefferies is bookrunner for offering
** Late Thurs, co said its lead compound, Hydronidone (F351), met primary endpoint in pivotal Phase III trial evaluating efficacy and safety for treatment of fibrosis in patients with chronic hepatitis B in China
** With ~93.8 mln shares outstanding as of May 1, co has ~$1bln market cap
** GYRE shares on Thurs rose 8.1% to $11.21, trimming YTD loss to ~7%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。